Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)
Author:
Affiliation:
1. Department of Drug Discovery, Exelixis, 169 Harbor Way, South San Francisco, California 94083, United States
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/jm3007933
Reference37 articles.
1. The tor pathway: a target for cancer therapy
2. Defining the Role of mTOR in Cancer
3. Dysregulation of the TSC-mTOR pathway in human disease
4. Rapamycin-insensitive Regulation of 4E-BP1 in Regenerating Rat Liver
Cited by 54 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Virtual screening of novel mTOR inhibitors for the potential treatment of human colorectal cancer;Bioorganic Chemistry;2023-11
2. Some New 1,2,4-triazole Derivatives Bearing the Pyrimidine Moiety as Potential Antimycobacterial Agents: Synthesis and Docking Analysis;Letters in Drug Design & Discovery;2023-10
3. Regulation of Eukaryotic Translation Initiation Factor 4E as a Potential Anticancer Strategy;Journal of Medicinal Chemistry;2023-09-19
4. Discovery of novel hybrids of mTOR inhibitor and NO donor as potential anti-tumor therapeutics;Bioorganic & Medicinal Chemistry;2023-08
5. The pathogenesis and development of targeted drugs in acute T lymphoblastic leukaemia;British Journal of Pharmacology;2023-02-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3